VOXZOGO 1.2MG
Biological
BioMarin Pharmaceutical Inc.
Total Payments
$6.2M
Transactions
737
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.7M | 458 | 3 |
| 2023 | $2.5M | 279 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.2M | 737 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia | BioMarin Pharmaceutical Inc. | $1.9M | 0 |
| An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | BioMarin Pharmaceutical Inc. | $1.1M | 0 |
| BMN 111-902 | BioMarin Pharmaceutical Inc. | $400,927 | 0 |
| A Phase 1, Randomized, Open-Label, Sponsor-Open, Two-Sequence, Two-Period Crossover Study to Investigate the Bioequivalence of a Single Subcutaneous Dose of BMN 111 Administered Using Either a Vial and Syringe or Injector Pen in Healthy Adult Participants | BioMarin Pharmaceutical Inc. | $375,892 | 0 |
| A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia | BioMarin Pharmaceutical Inc. | $315,500 | 0 |
| BMN 111-303 | BioMarin Pharmaceutical Inc. | $301,252 | 0 |
| A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers | BioMarin Pharmaceutical Inc. | $223,772 | 0 |
| BMN 111-903 | BioMarin Pharmaceutical Inc. | $207,130 | 0 |
| Vosoritide for Treatment of Short Stature in Girls with Turner Syndrome | BioMarin Pharmaceutical Inc. | $202,413 | 0 |
| BMN 111 Dominantly Inherited Short Stature Study | BioMarin Pharmaceutical Inc. | $189,481 | 0 |
| Proof of Concept Study of Vosoritide for the Treatment of Growth Deficits in MPS IVA & VI | BioMarin Pharmaceutical Inc. | $182,365 | 0 |
| Phase 2: Achondroplasia Natural History A multi-center cohort analysis with prospective subcohort study | BioMarin Pharmaceutical Inc. | $162,883 | 0 |
| A multi-center cohort study of achondroplasia | BioMarin Pharmaceutical Inc. | $130,249 | 0 |
| A Phase 1, Two Part, Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants | BioMarin Pharmaceutical Inc. | $125,297 | 0 |
| Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participating in the 165-302 study | BioMarin Pharmaceutical Inc. | $103,990 | 0 |
| A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia | BioMarin Pharmaceutical Inc. | $53,300 | 1 |
| Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients | BioMarin Pharmaceutical Inc. | $50,082 | 0 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children with Achondroplasia, Age 0 to < 60 Months | BioMarin Pharmaceutical Inc. | $49,292 | 0 |
| Proof of Concept Study to Evaluate the Safety and Efficacy of Voxzogo (vosoritide) for the Treatment of Growth Deficits in MPS IVA and VI | BioMarin Pharmaceutical Inc. | $45,591 | 0 |
| Multicenter multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in Study 111-202. No study drug is administered. | BioMarin Pharmaceutical Inc. | $29,904 | 0 |
Top Doctors Receiving Payments for VOXZOGO 1.2MG
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Northbrook, IL | $6.2M | 721 |
| , MD | Pediatric Critical Care Medicine | Charlottesville, VA | $3,150 | 9 |
| , M.D | Diagnostic Radiology | Dallas, TX | $790.00 | 3 |
| , M.D., PH.D | Diagnostic Radiology | Baltimore, MD | $750.00 | 2 |
| , M.D | Diagnostic Radiology | Abington, PA | $470.00 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $6.2M
- Total Doctors 4
- Transactions 737
About VOXZOGO 1.2MG
VOXZOGO 1.2MG is a biological associated with $6.2M in payments to 4 healthcare providers, recorded across 737 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2023 to 2024. In 2024, $3.7M was paid across 458 transactions to 3 doctors.
The most common payment nature for VOXZOGO 1.2MG is "Unspecified" ($6.2M, 100.0% of total).
VOXZOGO 1.2MG is associated with 20 research studies, including "A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia" ($1.9M).